daneng li, md, considers the role of cabozantinib and other tkis as hcc patients progress on i-o
Published 4 years ago • 61 plays • Length 3:22Download video MP4
Download video MP3
Similar videos
-
2:50
daneng li, md, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes
-
2:33
daneng li, md, on impressions of patient reported outcomes from the imbrave 150 study
-
1:58
daneng li, md, elaborates on the cosmic-312 trial in hepatocellular carcinoma
-
1:01:14
luncheon with the experts: daneng li, md
-
1:03:50
luncheon with the experts: daneng li, md
-
3:28
we are the face of cholangiocarcinoma
-
3:03
liver cancer stages
-
1:23:10
the future of machine learning in clinical imaging
-
4:56
liver cancer - causes, signs & symptoms, diagnosis, treatment | dr tan hon lyn (medical oncologist)
-
4:01
#raisetheline interview with chuck cairns- dean & sr vp of medical affairs, drexel college of med.
-
52:04
innate lymphoid cell/eosinophil collaboration re-shapes melanoma outcomes by dr. gabrielle belz
-
55:56
“update on the treatment of hepatocellular carcinoma and current research” by richard lee, md
-
0:36
nevena damjanov, md, on the outcomes of combining atezolizumab with bevacizumab in hcc patients
-
3:45
domore! • cancer and deep learning
-
0:21
what are #endothelial cells?
-
1:38
dr. li on preoperative immunotherapy in hepatocellular carcinoma
-
46:06
update on liver cancer - vatche g. agopian, md | ucla primary care update 2015
-
1:05
link between inflammation and pancreatic cancer development uncovered | cancer ed & res institute
-
7:13
2018 march author interview-dan li
-
1:32
bradley mcgregor, md, shares presented data investigating atezolizumab and cabozantinib in mcrpc
-
1:07
recent advancements for the treatment of liver cancer
-
0:56
meet oncologist daniel petrylak, md